Primary Prophylaxis of OIs

According to Stage of Immunodeficiency

CD4 count threshold/indication

CD4 count < 200 cells/µL, CD4 percentage < 14%, recurrent oral thrush, or relevant concomitant immunosuppression*

Prophylaxis against Pneumocystis jirovecii Pneumonia (PcP) & Toxoplasma gondii infection

Stop: if CD4 count > 100 cells/µL and HIV-VL undetectable over 3 months

* e.g. use of corticosteroids > 20 mg prednisone equivalent per day for > 2 weeks, cancer chemotherapy, biological agents such as rituximab and others.
Decisions on installation and discontinuation in these situations have to be taken individually

  Drug / Dose Comments
Positive or negative serology for
toxoplasmosis

trimethoprim sulfamethoxazole (TMP-SMX)
800/160 mg 3 x/week po OR

400/80 mg qd po or
800/160 mg qd po

 
Negative serology for toxoplasmosis pentamidine
300 mg in 6 mL sterile water 1 x inhalation/month
Does not prevent the rare extrapulmonary
manifestations of P. jirovecii
Negative serology for toxoplasmosis dapsone
1 x 100 mg qd po
Check for G6PD-deficiency
Negative serology for toxoplasmosis atovaquone suspension
1500 mg qd (with food)
 
Positive serology for toxoplasmosis dapsone 
200 mg/week po po
+ pyrimethamine 
75 mg/week po
+ folinic acid
25-30 mg/week po
Check for G6PD-deficiency
Positive serology for toxoplasmosis atovaquone suspension
1500 mg qd po (with food)
+/- pyrimethamine 
75 mg/week po
+ folinic acid 25-30 mg/week po
 
CD4 count < 50 cells/µL
Prophylaxis against Non-Tuberculous Mycobacteria (NTM) (M. avium complex, M. genavense, M. kansasii)
Prophylaxis is not recommended if ART is started
Prophylaxis may be considered for persons with CD4 counts < 50 cells/µL who remain viraemic on ART (drug resistant HIV with no option to achieve virologic control); exclude disseminated MAC disease before starting
Regimens listed are alternatives azithromycin
1200-1250 mg/week po
Check for interactions with ARVs, see Drug-drug Interactions between ARVs and Non-ARVs
or
clarithromycin
500 mg bid po
  or
rifabutin
300 mg qd po
Check for interactions with ARVs, see Drug-drug Interactions between ARVs and Non-ARVs